Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXGet Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of BTX stock opened at $0.25 on Tuesday. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10. The firm has a market capitalization of $14.71 million, a price-to-earnings ratio of -0.11 and a beta of 4.61. The stock’s 50-day simple moving average is $0.71 and its 200-day simple moving average is $1.33.

About Brooklyn ImmunoTherapeutics

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Featured Articles

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.